Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2006-06-27
2006-06-27
Murphy, Joseph (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S300000, C530S351000, C530S324000, C514S002600
Reexamination Certificate
active
07067117
ABSTRACT:
Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
REFERENCES:
patent: 4108855 (1978-08-01), Magó nee Karácsony et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4737580 (1988-04-01), Twardzik et al.
patent: 4774318 (1988-09-01), Marquardt et al.
patent: 5079228 (1992-01-01), Cohen et al.
patent: 5155038 (1992-10-01), Eyal et al.
patent: 5190918 (1993-03-01), Deutch et al.
patent: 5190920 (1993-03-01), Eyal et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202118 (1993-04-01), Gillis et al.
patent: 5212073 (1993-05-01), Rollins et al.
patent: 5248666 (1993-09-01), Twardzik et al.
patent: 5302384 (1994-04-01), Gimbrone, Jr. et al.
patent: 5357041 (1994-10-01), Roberts et al.
patent: 5401651 (1995-03-01), Walz
patent: 5426100 (1995-06-01), Deutch et al.
patent: 5458874 (1995-10-01), Pereira et al.
patent: 5459128 (1995-10-01), Rollins et al.
patent: 5474983 (1995-12-01), Kuna et al.
patent: 5491130 (1996-02-01), Roberts et al.
patent: 5556757 (1996-09-01), Alstyne et al.
patent: 5571713 (1996-11-01), Lyle et al.
patent: 5578714 (1996-11-01), Pogo et al.
patent: 5589458 (1996-12-01), Jameson et al.
patent: 5597578 (1997-01-01), Brown et al.
patent: 5605671 (1997-02-01), Lyle et al.
patent: 5627156 (1997-05-01), Talmadge
patent: 5627265 (1997-05-01), Frazier et al.
patent: 5645837 (1997-07-01), Jameson et al.
patent: 5646117 (1997-07-01), Matsushima et al.
patent: 5650150 (1997-07-01), Gillies
patent: 5661132 (1997-08-01), Eriksson et al.
patent: 5663294 (1997-09-01), Colman et al.
patent: 5684032 (1997-11-01), Elliot et al.
patent: 5700821 (1997-12-01), Lazo et al.
patent: 5705360 (1998-01-01), Rollins et al.
patent: 5707814 (1998-01-01), Levy et al.
patent: 5707815 (1998-01-01), Charo et al.
patent: 5770609 (1998-06-01), Grainger et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5817911 (1998-10-01), Williams et al.
patent: 5824551 (1998-10-01), Damme et al.
patent: 5824647 (1998-10-01), Postlethwaite et al.
patent: 5827821 (1998-10-01), Pierschbacher et al.
patent: 5831032 (1998-11-01), Schraufstatter et al.
patent: 5871740 (1999-02-01), Smith
patent: 5877276 (1999-03-01), Talmadge
patent: 5908829 (1999-06-01), Kelly
patent: 5955485 (1999-09-01), De Brabander et al.
patent: 5955492 (1999-09-01), Thompson et al.
patent: 0 281 363 (1988-09-01), None
patent: 0807439 (1997-11-01), None
patent: 0860446 (1998-08-01), None
patent: 0905241 (1999-03-01), None
patent: 2 319 252 (1998-05-01), None
patent: 36-14610 (1961-08-01), None
patent: 6-025288 (1994-02-01), None
patent: 7-67689 (1995-03-01), None
patent: 9-255570 (1996-03-01), None
patent: 86/04334 (1986-07-01), None
patent: WO 86/04334 (1986-07-01), None
patent: 90/07863 (1990-07-01), None
patent: 91/08483 (1991-06-01), None
patent: 91/17179 (1991-11-01), None
patent: 92/04372 (1992-03-01), None
patent: WO 92/04372 (1992-03-01), None
patent: WO-92/14455 (1992-09-01), None
patent: 92/20372 (1992-11-01), None
patent: 93/11159 (1993-06-01), None
patent: WO-93/10796 (1993-06-01), None
patent: 94/11014 (1994-05-01), None
patent: 94/20512 (1994-09-01), None
patent: WO 94/20512 (1994-09-01), None
patent: 95/05191 (1995-02-01), None
patent: 95/17420 (1995-06-01), None
patent: 95/17421 (1995-06-01), None
patent: 95/20973 (1995-08-01), None
patent: WO 9520973 (1995-08-01), None
patent: 95/26982 (1995-10-01), None
patent: 96/20722 (1996-07-01), None
patent: 96/22371 (1996-07-01), None
patent: WO-96/25157 (1996-08-01), None
patent: 97/01350 (1997-01-01), None
patent: 97/12615 (1997-04-01), None
patent: 97/19173 (1997-05-01), None
patent: 97/21812 (1997-06-01), None
patent: 97/22698 (1997-06-01), None
patent: 97/24325 (1997-07-01), None
patent: 97/25427 (1997-07-01), None
patent: WO 97/24325 (1997-07-01), None
patent: 97/29192 (1997-08-01), None
patent: 97/31098 (1997-08-01), None
patent: 97/32019 (1997-09-01), None
patent: 97/32993 (1997-09-01), None
patent: 97/35010 (1997-09-01), None
patent: 97/35982 (1997-10-01), None
patent: 97/44462 (1997-11-01), None
patent: 97/45543 (1997-12-01), None
patent: 98/06703 (1998-02-01), None
patent: 98/09171 (1998-03-01), None
patent: 98/12324 (1998-03-01), None
patent: WO 98/12324 (1998-03-01), None
patent: 98/13495 (1998-04-01), None
patent: 98/23750 (1998-06-01), None
patent: 98/24808 (1998-06-01), None
patent: WO-98/42354 (1998-10-01), None
patent: 98/00535 (1998-12-01), None
patent: 99/37617 (1999-07-01), None
patent: 99/37619 (1999-07-01), None
patent: 99/37651 (1999-07-01), None
patent: WO-00/00821 (2000-01-01), None
Gong JH, et al. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J. Exp. Med. Feb. 1, 1995;18(2):631-40.
Gong JH, et al. An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-Ipr Mouse Model. J. Exp. Med. Jul. 7, 1997;186(1):131-137.
Sozzani S. et al. Stimulating Properties of 5-Oxo-Eicosanoids for Human Monocytes. J. Immunol. 1996. 157:4664-4671.
Mikayama T. Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060, 1993.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc.. pp. 126-128 and 228-234.
Beers and Berkow, eds. The Merck Manual of Diagnosis and Therapy. Merck Research Laboratories, Whitehouse Station, N.J. 1999, pp. 1474-1476 and 895-902.
Fundamental Immunology, Fourth Edition, 1999, Paul, William ed. Lippincott-Raven, Philadelphia, PA, pp. 184-185.
“Blocking CCR5 Stops M-tropic HIV Infection”,Biotechnology News, 17, 3 (1997).
Adkins et al., “Zafirlukast—A Review of its Pharmacology and Therapeutic Potential in the Management of Asthma”,Drugs, 55, 121-144 (1998).
Albanesi et al., “Cetirizine and Hydrocortisone Differentially Regulate ICAM-I Expression and Chemokine Release in Cultured Human Keratinocytes”,Clinical and Experimental Allergy, 28, 101-109 (1998).
Alkhatib et al., “HIV-1 Coreceptor Activity of CCR5 and Its Inhibition by Chemokines: Independence from G Protein Signaling and Importance of Coreceptor Downmodulation”,Virology, 234, 340-348 (1997).
Arenzana-Seisdedos et al., “HIV Blocked by Chemokine Antagonists”,Nature, 383, 400 (1996).
Auer et al., “Crystallization and Preliminary X-ray Crystallographic Study of Interleukin-8”,FEBS Letters, 265, 30-32 (1990).
Bacon et al., “Activation of Dual T Cell Signaling Pathways by the Chemokine RANTES”,Science, 269, 1727-1730 (1995).
Bacon et al., “Chemokines in Disease Models and Pathogenesis”,Cytokine and Growth Factor Reviews, 9, 167-173 (1998).
Baldwin et al., “Crystal Structure of Interleukin 8: Symbiosis of NMR and Crystallography”,Proc. Natl. Acad. Sci. USA, 88, 502-506 (1991).
Baldwin et al., “Crystallization of Human Interleukin-8”,The Journal of Biological Chemistry, 265, 6851-6853 (1990).
Beck-Schimmer et al., “Hyaluronan Induces Monocyte Chemoattractant Protein-1 Expression in Renal Tubular Epithelial Cells”,Journal of the American Society of Nephrology, 9, 2283-2290 (1998).
Bernstein et al., “A Randomized Phase II Study of BB-10010: a Variant of Human Macrophage Inflammatory Protein-1alpha for Patients Receiving High-Dose Etoposide and Cyclophosphamide for Malignant Lymphoma and Breast Cancer”,British Journal of Haematology, 99, 888-895 (1997).
Bodaghi et al., “Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Excape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells”,J. Exp. Med., 188, 855-866 (1998).
Boring et al., “Decreased Lesion Formation in CCR2-/- Mice Reveals a Role for Chemokines in the Initiation of Atherosclerosis”,Nature, 394, 894-897 (1998).
Buckley, “Treatment of Rheumatoid Arthritis”,BMJ, 315, 236-238 (1997).
Cairns, J.S., et al., “Chemokines and HIV-1 Second Receptors: The Therapeutic Connection”,
Grainger David J.
Kanaly Suzanne T.
Tatalick Lauren Marie
Cambridge University Technical Services Ltd.
Murphy Joseph
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Compounds and methods to inhibit or augment an inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods to inhibit or augment an inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods to inhibit or augment an inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693341